Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Zanichelli, A; Maurer, M; Aberer, W; Caballero, T; Longhurst, HJ; Bouillet, L; Fabien, V; Andresen, I; IOS Study Group.
Long-term safety of icatibant treatment of patients with angioedema in real-world clinical practice.
Allergy. 2017; 72(6):994-998 Doi: 10.1111/all.13103 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Aberer Werner
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
The Icatibant Outcome Survey (IOS) is an observational study monitoring safety and effectiveness of icatibant in the real-world setting. We analyzed safety data from 3025 icatibant-treated attacks in 557 patients (enrolled between July 2009 and February 2015). Icatibant was generally well tolerated. Excluding off-label use and pregnancy, 438 patients (78.6%) did not report adverse events (AEs). The remaining 119 (21.4%) patients reported 341 AEs, primarily gastrointestinal disorders (19.6%). Of these, 43 AEs in 17 patients (3.1%) were related to icatibant. Serious AEs (SAEs) occurred infrequently. A total of 143 SAEs occurred in 59 (10.6%) patients; only three events (drug inefficacy, gastritis, and reflux esophagitis) in two patients were considered related to icatibant. Notably, no SAEs related to icatibant occurred in patients with cardiovascular disease, nor in those using icatibant at a frequency above label guidelines. Additionally, no major differences were noted in AEs occurring in on-label vs off-label icatibant users. © 2016 The Authors. Allergy Published by John Wiley & Sons Ltd.
Find related publications in this database (using NLM MeSH Indexing)
Adolescent -
Angioedema - drug therapy
Anti-Inflammatory Agents, Non-Steroidal -
Bradykinin - adverse effects
Bradykinin - analogs & derivatives
Bradykinin - therapeutic use
Cardiovascular Diseases -
Female -
Gastrointestinal Diseases - chemically induced
Humans -
Male -
Off-Label Use - standards
Time Factors -
Treatment Outcome -

Find related publications in this database (Keywords)
angioedema
icatibant
real-world
safety
© Med Uni Graz Impressum